Experience of dapagliflozin use in elderly female patients with hyperactive urinary bladder


DOI: https://dx.doi.org/10.18565/therapy.2024.1.16-20

Yuzhakova E.V., Smirnova E.N.

Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia
Abstract. Hyperactive urinary bladder (HAUB) is common in type 2 diabetes mellitus (T2DM) and may be a factor limiting use of sodium-glucose co-transporter 2 inhibitors (SGLT2). Current studies demonstrate an increased risk of urinary tract infections (UTIs) development during SGLT2 therapy, which may be facilitated by HAUB.
The aim: to evaluate the effect of dapagliflozin therapy at HAUB clinical course in T2DM female patients and possibilities of using herbal uroseptic containing extracts of centaury herb, lovage roots and rosemary leaves for recurrent UTIs’ development prevention.
Material and methods. An outpatient examination of 18 female patients with T2DM and HAUB was carried out. The median age of the patients was 72 (68–79) years. Dapagliflozin at a dose of 10 mg was selected from SGLT2; it was added to the existing glucose-lowering therapy. Follow-up questionnaire, general urine analysis were performed after 1 and 3 months, and urination diaries were assessed after a month of SGLT-2 use.
Results. Initially, 11 patients had a mild degree of urinary disorder, and 7 had a moderate degree. A month later, during SNGLT-2 therapy, mild severity of urinary disorder took place in 8, moderate – in 4, severe – in 6 female participants of the study. There was a significantly valid increase in urination frequency, minimum and maximum urine volumes. In 7 female patients with initially moderate degree of urinary disturbances, a deterioration in HAUB clinical course was recorded, which was facilitated by urinary tract infection. Asymptomatic bacteriuria was detected in 7 out of 11 females with initially mild urinary disorder. After antibiotic therapy for complicated cystitis and asymptomatic bacteriuria, 14 patients continued taking dapagliflozin. Additionally, monthly administration of a herbal uroseptic for 10 days was recommended. Follow-up examination after 3 months showed no worsening of HAUB.
Conclusion. Taking SGLT-2 inhibitors in elderly female patients with T2DM and HAUB increases the risk of developing urinary tract infections. For patients with mild urinary disorders receiving gliflozin, it is advisable to recommend an uroseptic containing extracts of centaury herb, lovage roots and rosemary leaves for 10 days of each month. In case of moderate to severe HAUB, it is preferable to use incretins.
Keywords: hyperactive urinary bladder, dapagliflozin, lower urinary tract infections, type 2 diabetes mellitus
Read entire article

Literature

1. Анциферов М.Б., Галстян Г.Р., Демидова Т.Ю. с соавт. Резолюция совета экспертов по актуальным вопросам применения ингибиторов натрий-глюкозного котранспортера 2-го типа и агонистов рецепторов глюкагоноподобного пептида 1 в терапии сахарного диабета 2 типа. Сахарный диабет. 2023; 26(2): 211–214. (Antsiferov M.B., Galstyan G.R., Demidova T.Yu. et al. Expert Council on a resolution on current issues of the use of sodium-glucose cotransporter type 2 inhibitors and glucagon-like peptide 1 receptor agonists in the treatment of type 2 diabetes mellitus. Sakharnyy diabet = Diabetes Mellitus. 2023; 26(2): 211–214 (In Russ.)). https://doi.org/10.14341/DM13034. EDN: NRJUFI.


2. Arnott C., Li Q., Kang A. et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J Am Heart Assoc. 2020; 9(3): e014908. https://doi.org/10.1161/JAHA.119.014908. PMID: 31992158. PMCID: PMC7033896.


3. Neuen B.L., Yong T., Heerspink H.J.L. et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Deabetes Endocrinol. 2019; 7(11): 845–54. https://doi.org/10.1016/S2213-8587(19)30256-6. PMID: 31495651.


4. Xu D., Cheng R., Ma A. et al. Toileting behaviors and overactive bladder in patients with type 2 diabetes: A cross-sectional study in China. BMC Urol. 2017; 17(1): 42. https://doi.org/10.1186/s12894-017-0234-2. PMID: 28610556. PMCID: PMC5470265.


5. Johnston S., Janning S.W., Haas G.P. et al. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes. Int J Clin Pract. 2012; 66(11): 1042–51. https://doi.org/10.1111/j.1742-1241.2012.03009.x. PMID: 23067028.


6. Uitrakul S., Aksonnam K., Srivichai P. et al. The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: A real-world observational study. Medicines (Basel). 2022; 9(12): 59. https://doi.org/10.3390/medicines9120059. PMID: 36547992. PMCID: PMC9785475.


7. Hazique M., Surana A., Sinha M., Anand A. Recurrent urinary tract infection associated with SGLT-2 inhibitor in type 2 diabetes mellitus patient: A case report. Clin Case Rep. 2023; 11(1): e6803. https://doi.org/10.1002/ccr3.6803. PMID: 36619486. PMCID: PMC9811059.


8. Клинические рекомендации ЕАУ-2023 по инфекциям мочевых путей. Доступ: https://uroweb.ru/sites/default/files/2023_kp_eau_imp_urohub.pdf (дата обращения – 22.01.2024) (Clinical guidelines EAU-2023 on urinary tract infections. URL: https://uroweb.ru/sites/default/files/2023_kp_eau_imp_urohub.pdf (date of access – 22.01.2024) (In Russ.)).


9. Khan S., Hashimi M., Rana M.A et al. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022; 14(1): e21720. https://doi.org/10.7759/cureus.21720. PMID: 35251794. PMCID: PMC8887691.


10. Малявин А.Г., Губернаторова Е.Е., Бабак С.Л. Применение препарата Канефрон Н при симптомах острого цистита у женщин с сахарным диабетом 2-го типа, получающих ингибиторы натрий-глюкозного котранспортера-2. Терапия. 2023; 9(8): 152–161. (Malyavin A.G., Gubernatorova E.E., Babak S.L. The use of Canephron H for symptoms of acute cystitis in women with type 2 diabetes mellitus receiving sodium-glucose cotransporter-2 inhibitors. Terapiya = Therapy. 2023; 9(8): 152–161 (In Russ.)). https://doi.org/10.18565/therapy.2023.8.152-161. EDN: YWZBXA.


11. Цыганкова О.В., Евдокимова Н.Е., Тимошенко О.В., Латынцева Л.Д. Влияние лекарственного растительного препарата на частоту обострений цистита и метаболические параметры у пациенток с диабетом 2-го типа, принимающих глифлозины. Терапевтический архив. 2023; 95(8): 664–669. (Tsygankova O.V., Yevdokimova N.E., Timoshenko O.V., Latyntseva L.D. The effect of a medicinal herbal preparation on the frequency of exacerbations of cystitis and metabolic parameters in patients with type 2 diabetes taking gliflozin. Terapevticheskiy arkhiv = Therapeutic Archive. 2023; 95(8): 664–669 (In Russ.)). https://doi.org/10.26442/00403660.2023.08.202362. EDN: IJZYIC.


About the Autors

Ekaterina V. Yuzhakova, MD, PhD (Medicine), associate professor of the Department of endocrinology and clinical pharmacology, Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia. Address: 614045, Perm, 85 Pushkina St.
E-mail: uzkaty@mail.ru
ORCID: https://orcid.org/0000-0001-5262-9378
Elena N. Smirnova, MD, Dr. Sci. (Medicine), professor, head of the Department of endocrinology and clinical pharmacology, Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia. Address: 614045, Perm, 85 Pushkina St.
E-mail: elenasm2001@mail.ru
ORCID: https://orcid.org/0000-0003-2727-5226


Similar Articles

Back to Content

Бионика Медиа